Tower Research Capital (TRC)’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
Tower Research Capital (TRC)'s PRVL Position: Q1 2021 in Review
Tower Research Capital (TRC) sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 838 shares — an estimated $19K sold.
Tower Research Capital (TRC) first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $96K in Q3 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.
- Tower Research Capital (TRC) reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 838 Prevail Therapeutics shares in Q1 2021, an estimated $19K.
- Tower Research Capital (TRC) first reported a position in Prevail Therapeutics in Q2 2019 and held it in 6 quarters.
- Tower Research Capital (TRC)'s Prevail Therapeutics position peaked at $96K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2021, filed 17 May 2021.